85%Confidence
0Views
FDASource
2026-04-20Date
Summary
Fagron faces a product recall due to sterility concerns and a potential for particulate contamination from a device component. This signals quality control issues in its compounding services, which could impact its reputation and lead to regulatory scrutiny.
Actionable: Monitor Fagron's stock for potential volatility and assess the financial impact of the recall and any corrective actions.
AI Confidence: 85%
Data Points
firmFagron Compounding Services
classificationClass II
statusOngoing
distributionNationwide in the U.S.A.
productVancomycin HCI, 1.5 grams added to 250 mL, 0.9% Sodium Chloride Injection USP, Fagron Sterile Services, 8710 34th St. N. Wichita, KS 67226, NDC 71266-
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now